• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Certara acquires Simcyp, adding preclinical research capability

Certara acquires Simcyp, adding preclinical research capability

March 1, 2012
CenterWatch Staff

Certara, a provider of drug discovery and development software and scientific consulting services, will acquire U.K-based Simcyp, a research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations.

Simcyp will join the Certara portfolio and provide key, extensible technologies that support Certara’s translational science initiatives.

“The capabilities offered by Simcyp’s preclinical technologies, combined with our existing software products and scientific consulting services, will provide significant drug development advantages to our mutual and prospective clients,” said Jim Hopkins, CEO and president of Cerara. “This means broader capabilities to predict drug disposition as a function of molecular structure, and the ability to utilize a single unified suite of tools to facilitate preclinical and clinical PBPK and PKPD modeling and analysis.”

Clients from across the spectrum of drug discovery and development will have access to an expanded and integrated range of products and services, through the combination of Tripos, Simcyp and Pharsight science and functionality, according to Hopkins.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing